Biodesix Q3 revenue $21.8M (+20% YoY); raises FY2025 guidance to $84-86M

BIODESIX INC

2025-Q3 EPS reported -$4.24 revenue$59,744,000

Q3 2025 revenue $21.8M, up 20% YoY; gross margin 81% (up 400 bps YoY).
Net loss $8.7M, a 15% improvement YoY; Adjusted EBITDA loss $4.6M, improvement of 18%.
Lung diagnostic testing revenue $19.8M (+16% YoY); Development Services $1.9M (+97% YoY).
Raised FY2025 total revenue guidance to $84-86M from prior range.
Cash $16.6M at Sept 30; accounts receivable increase $5.2M due to timing of collections.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.